Zenas BioPharma’s stock climbed 33% following a positive mid-phase trial readout for its lead candidate, obexelimab, in ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...

TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated ...

A pivotal clinical development has sent Zenas BioPharma (NASDAQ: ZBIO) shares climbing higher, reshaping the company’s ...

OID 2025 is part of the lead-up activities to the Autumn Economic Forum (HEF) 2025, directed by the People's Committee of Ho ...